StockData
Dyne Therapeutics, Inc. logo

Dyne Therapeutics, Inc. (DYN) stock

DYNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$16.02−0.68 (-4.07%)

Close on Nov 17, 2026Market cap $2.99BP/E –Yield –

Dyne Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Dyne Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$536.96M. For fiscal 2025 it was -$468.18M. The highest annual figure on record is -$13.83M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$468.18M–
FY2024Dec 31, 2024-$343.89M–
FY2023Dec 31, 2023-$242.16M–
FY2022Dec 31, 2022-$170.96M–
FY2021Dec 31, 2021-$150.03M–
FY2020Dec 31, 2020-$58.65M–
FY2019Dec 31, 2019-$13.83M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$181.66M–
Q1 FY2026Mar 31, 2026-$125.28M–
Q4 FY2025Dec 31, 2025-$116.13M–
Q3 FY2025Sep 30, 2025-$113.89M–
Q2 FY2025Jun 30, 2025-$115.79M–
Q1 FY2025Mar 31, 2025-$122.37M–
Q4 FY2024Dec 31, 2024-$97.11M–
Q3 FY2024Sep 30, 2024-$105.57M–
Q2 FY2024Jun 30, 2024-$71.96M–
Q1 FY2024Mar 31, 2024-$69.16M–
Q4 FY2023Dec 31, 2023-$67.69M–
Q3 FY2023Sep 30, 2023-$62.27M–
Q2 FY2023Jun 30, 2023-$66.74M–
Q1 FY2023Mar 31, 2023-$45.46M–
Q4 FY2022Dec 31, 2022-$40.15M–
Q3 FY2022Sep 30, 2022-$42.28M–
Q2 FY2022Jun 30, 2022-$52.76M–
Q1 FY2022Mar 31, 2022-$35.78M–
Q4 FY2021Dec 31, 2021-$51.96M–
Q3 FY2021Sep 30, 2021-$42.77M–
Q2 FY2021Jun 30, 2021-$30.17M–
Q1 FY2021Mar 31, 2021-$25.13M–
Q4 FY2020Dec 31, 2020-$28.60M–
Q3 FY2020Sep 30, 2020-$13.52M–
Q2 FY2020Jun 30, 2020-$8.68M–
Q1 FY2020Mar 31, 2020-$7.85M–
Q4 FY2019Dec 31, 2019-$5.47M–
Q3 FY2019Sep 30, 2019-$3.63M–

More Dyne Therapeutics figures

See a number that looks wrong?